--- title: "Opthea Limited (OPTEY.US)" type: "quote" locale: "en" url: "https://longbridge.com/en/quote/OPTEY.US.md" symbol: "OPTEY.US" name: "Opthea Limited" industry: "生物技术" --- # Opthea Limited (OPTEY.US) | Item | Detail | |------|--------| | Industry | 生物技术 | | Location | 美股市场 | | Website | [opthea.com](https://opthea.com) | ## Financial Score > *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.* > Updated: 2026-02-21T04:30:13.000Z **Overall: D (0.75)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 334 / 403 | | Industry Median | D | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. ### Score Analysis **Style Score**: #### Growth Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -44.27% | | | Net Profit YoY | 26.09% | | #### Value Score: | Indicator | Value | Rating | |-----------|-------|--------| | P/B Ratio | -0.01 | | | Dividend Ratio | 0.00% | | **Size Score**: #### Market Cap Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 2.39M | | #### Revenue Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue | 146000.00 | | **Multi Score**: D #### Profit Score: B | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 117.59% | A | | Profit Margin | -111500.68% | E | | Gross Margin | 100.00% | A | #### Growth Score: E | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | -44.27% | E | | Net Profit YoY | 26.09% | B | | Total Assets YoY | -69.91% | E | | Net Assets YoY | -165.23% | E | #### Cash Score: D | Indicator | Value | Rating | |-----------|-------|--------| | Cash Flow Margin | -0.09% | D | | OCF YoY | -44.27% | E | #### Operating Score: E | Indicator | Value | Rating | |-----------|-------|--------| | Turnover | 0.00 | E | #### Debt Score: E | Indicator | Value | Rating | |-----------|-------|--------| | Gearing Ratio | 454.00% | E | ```chart-data:radar { "title": "Longbridge Financial Score - Opthea Limited", "chart_type": "radar", "dimensions": [ { "name": "Profit", "grade": "B", "indicators": [ { "name": "ROE", "value": "117.59%", "rating": "A" }, { "name": "Profit Margin", "value": "-111500.68%", "rating": "E" }, { "name": "Gross Margin", "value": "100.00%", "rating": "A" } ] }, { "name": "Growth", "grade": "E", "indicators": [ { "name": "Revenue YoY", "value": "-44.27%", "rating": "E" }, { "name": "Net Profit YoY", "value": "26.09%", "rating": "B" }, { "name": "Total Assets YoY", "value": "-69.91%", "rating": "E" }, { "name": "Net Assets YoY", "value": "-165.23%", "rating": "E" } ] }, { "name": "Cash", "grade": "D", "indicators": [ { "name": "Cash Flow Margin", "value": "-0.09%", "rating": "D" }, { "name": "OCF YoY", "value": "-44.27%", "rating": "E" } ] }, { "name": "Operating", "grade": "E", "indicators": [ { "name": "Turnover", "value": "0.00", "rating": "E" } ] }, { "name": "Security", "grade": "E", "indicators": [ { "name": "Gearing Ratio", "value": "454.00%", "rating": "E" } ] } ] } ``` ### Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | |------|------|--------|--------|-----------|----------|------|--------| | 01 | ADMA生物制药 (US.ADMA) | A | A | A | B | B | A | | 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A | | 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A | | 04 | Rigel制药 (US.RIGL) | A | A | A | C | B | A | | 05 | OpGen (US.OPGN) | B | A | A | A | B | A | ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -0.01 | 71/604 | - | - | - | | PB | -0.01 | 452/604 | - | - | - | | PS (TTM) | 16.40 | 189/604 | 74.66 | 40.99 | 20.14 | | Dividend Yield | 0.00% | - | - | - | - | ## Institutional View ### Analyst Rating Distribution > As of 2026-02-13T05:00:00.000Z Total Analysts: **1** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 0 | 0% | | Overweight | 0 | 0% | | Hold | 1 | 100% | | Underweight | 0 | 0% | | Sell | 0 | 0% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 0.01 | | Highest Target | 1.00 | | Lowest Target | 1.00 | ## References - [Company Overview](https://longbridge.com/en/quote/OPTEY.US/overview.md) - Shareholders, executives, business segments - [Financials](https://longbridge.com/en/quote/OPTEY.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan - [Topics & Discussions](https://longbridge.com/en/quote/OPTEY.US/topics.md) - Community topics and discussions --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.